Screener
Design Therapeutics, Inc. DSGN Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-187063
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development (including related party amounts of $72 and $228, respectively) | $14,379 | $15,377 |
| General and administrative (including related party amounts of $85 and $134, respectively) | 5,327 | 5,041 |
| Total operating expenses | 19,706 | 20,418 |
| Loss from operations | (19,706) | (20,418) |
| Interest income | 2,070 | 2,703 |
| Net loss | $(17,636) | $(17,715) |
| Net loss per share, basic and diluted | $(0.29) | $(0.31) |
| Weighted-average shares of common stock outstanding, basic and diluted | 61,434,457 | 56,757,827 |
Item 1. Financial Statements.
FAQ
- What is Design Therapeutics, Inc.'s net income?
- Design Therapeutics, Inc. (DSGN) reported net income of -$17.64M in Q1 2026.
- How has Design Therapeutics, Inc.'s net income changed year-over-year?
- Design Therapeutics, Inc.'s net income increased by 0.4% year-over-year, from -$17.72M to -$17.64M.
- What is the long-term trend for Design Therapeutics, Inc.'s net income?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s net income has grown at a 18.4% compound annual growth rate (CAGR), from -$35.53M to -$69.79M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Design Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude